Data Tells a Story: Psychedelic Research in the Digital Age

We are currently in the midst of a historic resurgence of clinical research aimed at developing therapeutic applications for psychedelic drugs such as psilocybin, ketamine, and MDMA. The Multidisciplinary Association for Psychedelic Studies (MAPS) has been utilizing Medrio products since 2013 to conduct Phase 2 and Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder and other indications. In this talk, Ben Shechet will discuss MAPS’s work as an example of a small, nonprofit pharmaceutical company using Medrio’s database management tools to engage in novel clinical research. We will discuss the history and context of this research, Phase 2 outcome data for MDMA-assisted psychotherapy projects, current Phase 3 research, and lessons and improvements in database design and clinical processes that may be useful to other small pharmaceutical companies engaged in drug development work.
Presented by
Benjamin Shechet

Research Coordinator, Scottsdale Research Institute 

Jeffery Doten
Professional Services Project Manager. Medrio

Jeffery Doten is a Professional Services Project Manager at Medrio. Jeffery is an educator, health promotion specialist, and technology enthusiast. He has a Public Health background and has worked in technology since 2008. Over the last 4 years, his focus has been on Clinical Technology software, working with EDC and IWRX platforms to help studies build software, stay on schedule and collect great data. At Medrio, Jeffery’s primary responsibilities center on user education and custom project management.

Speaker Name
Speaker Title

Sed ac purus sit amet nisl tincidunt tincidunt vel at dolor. In ullamcorper nisi risus, quis fringilla nibh mattis ac. Mauris interdum interdum eros, eget tempus lectus aliquet at. Suspendisse convallis suscipit odio, ut varius enim lacinia in. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Watch Now!